ArticleHematology, transfusion and cell therapy2026
Clinical characteristics, prognosis, and achievement of transplant in adolescents and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in Argentina.
Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionData on clinical outcomes and allogeneic stem cell transplantation for Latin American Philadelphia chromosome-negative acute lymphoblastic leukemia patients are limited. This study aimed to characterize this population and identify factors influencing overall survival among adolescents and adults with this malignancy in Argentina. Additionally, the study examined the predictors of proceeding to first-line allogeneic stem cell transplantation in this population.
methodsThis retrospective cohort study included patients diagnosed at 15 centers between 2014 and 2022. Descriptive, univariate, and multivariate analyses were conducted.
resultsThree hundred and five patients with a median age of 34 years were included. Median overall survival was 42 months. Treatment at public healthcare institutions (hazard ratio: 1.61), central nervous system involvement (hazard ratio: 1.56), high-risk status defined by the receipt of Berlin-Frankfurt-Münster-like or hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimens (hazard ratio: 1.89), and older age (hazard ratio: 1.02) were independently associated with a worse outcome. In a subgroup analysis of 199 patients with an indication and eligibility to receive allogeneic stem cell transplantation, 20.1% underwent the procedure. Receiving treatment at public institutions was associated with a 65% lower likelihood of undergoing transplantation (p-value = 0.013), an effect that remained consistent when death or relapse was accounted for as a competing event (Subdistribution Hazard Ratio: 0.28).
conclusionsIn this acute lymphoblastic leukemia Argentinean cohort, overall survival was influenced by classical predictors of a worse outcome and by healthcare disparities. Receiving treatment at public institutions adversely diminished access to first-line allogeneic stem cell transplantation, which may account for the poorer outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.